

BIOAFTOGEN®

The World Champion in FMD Control & Eradication




ONE WORLD - ONE HEALTH - ONE VACCINE

The evolution of animal health



BIOAFTOGEN®

The Best and Safest Choice for FMD Risk Management



● HIGH SAFETY

Safe for use in all susceptible species, across all production and reproductive stages.

● STRONG PROTECTION

Early onset and long-lasting immunity with broad cross-protection against circulating FMD strains.

● STABLE POTENCY

>32 PD₅₀. Maintains efficacy throughout a 24-month shelf life.

● DIVA CAPABILITY

Differentiates vaccinated animals from natural infections, essential for control and eradication programs.

BIOAFTOGEN® FMD Vaccine O+A is a high-potency, inactivated, oil-adjuvanted vaccine with validated cross-protection against circulating FMD virus strains worldwide.



Vaccine strains with high antigenic coverage

- ✓ O1 Campos
- ✓ A24 Cruzeiro
- ✓ A2001 Argentina



Advanced adjuvant and formulation

- ✓ Single water-in-oil emulsion technology
- ✓ Proven safety for animals
- ✓ Optimized for strong and long-lasting immune response



Pure antigens

- ✓ Highly purified antigens
- ✓ Produced in high-containment biosafety facilities
- ✓ DIVA compliant



Trusted quality standards

- ✓ Manufactured in compliance with GMP, ISO 9001 and ISO 14001
- ✓ Independent batch release by SENASA (Argentina) and veterinary authorities of destination countries
- ✓ Constantly validated cross-protection by WRLFMD



High potency vaccine

>32 PD₅₀

Exceeding WOA standards for emergency vaccination

Broad immunological cross reactivities



Scan the QR code to explore the cross-protection of **BIOAFTOGEN®** vaccine strains against field isolates from different serotypes and topotypes across the world.



VACCINE PERFORMANCE

BIOAFTOGEN® delivers robust and reliable protection under field conditions




EARLY PROTECTION

from day 7 post-vaccination



DURATION OF IMMUNITY

>6 months (180 days)



STRONG IMMUNE RESPONSE

even with high levels of maternal antibodies

BIOAFTOGEN® FMD VACCINE

Worldwide presence



Over 35 licenses
in more than
30 countries

First FMD vaccine
to obtain the EuFMD
Pre-qualification

350 million doses
per year of
manufacturing
capacity

EMERGENCIES ATTENDED



BIOAFTOGEN® is the strategic solution for sustainable FMD risk management.



Dosage and Route of Administration

Cattle, Buffalo and Swine: 2mL per dose

Sheep and Goats: 1mL per dose

Administer by intramuscular (IM) injection

Following Good Vaccination Practices



**Biogénesis
Bagó**

BIOGÉNESIS BAGÓ, A GLOBAL LEADER IN FMD PREVENTION

Biogénesis Bagó is a global biotechnology leader dedicated to advancing animal health, present across five continents and more than 60 countries. With over 70 years of continuous innovation, FMD prevention is at the core of our expertise.

Our **BIOAFTOGEN® PLATFORM** feature a comprehensive range of well-characterized strains, available in multiple formulations from monovalent to hexavalent, delivering broad antigenic coverage and consistent quality to meet the diverse needs of global markets.



ANTIGEN AND VACCINE BANK

Biogénesis Bagó operates one of the world's most comprehensive FMD antigen banks, enabling rapid vaccine response within 7 days during foot-and-mouth disease emergencies.



ARGENTINA
Since 2001



USA - CANADA
2006-2032
North America
FMD Antigen and
Vaccine Bank



TAIWAN
Since 2019



USA (APHIS)
2020-2037
NAVVCB
National Bank of Animal
Vaccines and Veterinary
Countermeasures



S. KOREA
Since 2022
APQA
Animal Plant and
Quarantine Agency



CANADA
2025-2039
Canadian FMD
Vaccine Bank



BRAZIL
2025-2035
TECPAR
FMD antigen and vaccine
bank, in partnership with
the Paraná Institute of
Technology

PROVEN GLOBAL SUCCESS STORIES IN FMD CONTROL PROGRAMS WORLDWIDE



Latin America: Biogénesis Bagó has played a key role in South America's FMD eradication success, with no outbreaks reported since 2018.



Trusted supplier to national FMD vaccine banks in leading livestock producing countries, protecting over 1.1 billion susceptible animals.



South Africa: Selected as a strategic partner for rapid emergency response, supplying high-potency SAT 1, SAT 2, SAT 3 vaccines for national outbreak control from January 2026.



Taiwan: Key contribution from emergency response in 1997 to achieving FMD-free status, and selected as supplier to the National Vaccine Bank since 2019.

Biogénesis Bagó is committed to FMD control and eradication, actively supporting national and regional programs with high-quality, potent, and safe FMD vaccines.